Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502161 · ClinicalTrials.gov registry record
Clinical Evaluation of the QuantiFERON CMV Assay
A clinical trial, sponsored by QIAGEN Gaithersburg.
- Terminated
- Registry status
- 8
- Enrollment target
NCT03502161 is a clinical trial that was terminated before completion, run by QIAGEN Gaithersburg. The registered enrollment target is 8 participants.
The verdict
NCT03502161 was terminated before completion, sponsored by QIAGEN Gaithersburg.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
Interventions
- DEVICE QuantiFERON CMV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2020-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03502161
The ClinicalTrials.gov registry entry for NCT03502161 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QIAGEN Gaithersburg, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QuantiFERON CMV Assay is the first listed.
NCT03502161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03502161 about?
NCT03502161 is a clinical study titled "Clinical Evaluation of the QuantiFERON CMV Assay". Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
What is the current status of trial NCT03502161?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2018-11-15. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03502161?
The interventions under investigation include: QuantiFERON CMV Assay (DEVICE).
Who is sponsoring clinical trial NCT03502161?
This trial is sponsored by QIAGEN Gaithersburg, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.